Caas Capital Management LP Atreca, Inc. Transaction History

Caas Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $202,673 - $654,596	-125,884 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $361,287 - $791,810	125,884 New	125,884 $381,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $210,859 - $389,511	-42,945 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $335,829 - $592,641	42,945 New	42,945 $366,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.